Is GKOS or PLSE more profitable?

Pulse Biosciences has a net margin of 0.00% compared to Glaukos' net margin of -30.68%. Glaukos' return on equity of -6.37% beat Pulse Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Glaukos -30.68% -6.37% -4.78% Pulse Biosciences N/A -86.67% -73.61%

Does the media favor GKOS or PLSE?

In the previous week, Glaukos had 8 more articles in the media than Pulse Biosciences. MarketBeat recorded 14 mentions for Glaukos and 6 mentions for Pulse Biosciences. Glaukos' average media sentiment score of 0.82 beat Pulse Biosciences' score of -0.46 indicating that Glaukos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 8 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pulse Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to TFX or PLSE?

In the previous week, Teleflex had 21 more articles in the media than Pulse Biosciences. MarketBeat recorded 27 mentions for Teleflex and 6 mentions for Pulse Biosciences. Teleflex's average media sentiment score of 0.73 beat Pulse Biosciences' score of -0.46 indicating that Teleflex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teleflex 9 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pulse Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PLSE or MMED more profitable?

MiniMed Group's return on equity of 0.00% beat Pulse Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Pulse Biosciences N/A -86.67% -73.61% MiniMed Group N/A N/A N/A

Does the media refer more to PLSE or MMED?

In the previous week, Pulse Biosciences had 5 more articles in the media than MiniMed Group. MarketBeat recorded 6 mentions for Pulse Biosciences and 1 mentions for MiniMed Group. MiniMed Group's average media sentiment score of 1.34 beat Pulse Biosciences' score of -0.46 indicating that MiniMed Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulse Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MiniMed Group 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PLSE or LIVN?

In the previous week, LivaNova had 10 more articles in the media than Pulse Biosciences. MarketBeat recorded 16 mentions for LivaNova and 6 mentions for Pulse Biosciences. LivaNova's average media sentiment score of 0.92 beat Pulse Biosciences' score of -0.46 indicating that LivaNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulse Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral LivaNova 6 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, PLSE or ITGR?

Integer has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pulse Biosciences $350K 8,386.27 -$72.78M -$1.10 N/A Integer $1.85B 2.29 $102.81M $4.01 31.19

Does the media prefer PLSE or ITGR?

In the previous week, Integer had 29 more articles in the media than Pulse Biosciences. MarketBeat recorded 35 mentions for Integer and 6 mentions for Pulse Biosciences. Integer's average media sentiment score of 0.69 beat Pulse Biosciences' score of -0.46 indicating that Integer is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulse Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Integer 17 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Pulse Biosciences (PLSE) Competitors

$42.41 +4.17 (+10.90%)

Closing price 04:00 PM Eastern

Extended Trading

$42.23 -0.18 (-0.42%)

As of 04:21 PM Eastern

Compare

PLSE vs. GKOS, TFX, MMED, LIVN, and ITGR

Should you buy Pulse Biosciences stock or one of its competitors? MarketBeat compares Pulse Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pulse Biosciences include Glaukos (GKOS), Teleflex (TFX), MiniMed Group (MMED), LivaNova (LIVN), and Integer (ITGR). These companies are all part of the "healthcare equipment" industry.

How does Pulse Biosciences compare to Glaukos?

Glaukos (NYSE:GKOS) and Pulse Biosciences (NASDAQ:PLSE) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

Pulse Biosciences has a net margin of 0.00% compared to Glaukos' net margin of -30.68%. Glaukos' return on equity of -6.37% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-30.68%	-6.37%	-4.78%
Pulse Biosciences	N/A	-86.67%	-73.61%

99.0% of Glaukos shares are owned by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are owned by institutional investors. 5.9% of Glaukos shares are owned by insiders. Comparatively, 74.0% of Pulse Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Glaukos currently has a consensus target price of $177.33, indicating a potential downside of 1.61%. Pulse Biosciences has a consensus target price of $32.33, indicating a potential downside of 23.76%. Given Glaukos' stronger consensus rating and higher probable upside, equities analysts plainly believe Glaukos is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Glaukos had 8 more articles in the media than Pulse Biosciences. MarketBeat recorded 14 mentions for Glaukos and 6 mentions for Pulse Biosciences. Glaukos' average media sentiment score of 0.82 beat Pulse Biosciences' score of -0.46 indicating that Glaukos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	8 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pulse Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pulse Biosciences has lower revenue, but higher earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Pulse Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$612.84M	17.35	-$187.69M	-$3.25	N/A
Pulse Biosciences	$350K	8,386.27	-$72.78M	-$1.10	N/A

Glaukos has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.61, meaning that its stock price is 61% more volatile than the broader market.

Summary

Glaukos beats Pulse Biosciences on 9 of the 16 factors compared between the two stocks.

How does Pulse Biosciences compare to Teleflex?

Teleflex (NYSE:TFX) and Pulse Biosciences (NASDAQ:PLSE) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

95.6% of Teleflex shares are held by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are held by institutional investors. 0.7% of Teleflex shares are held by company insiders. Comparatively, 74.0% of Pulse Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Pulse Biosciences has lower revenue, but higher earnings than Teleflex. Pulse Biosciences is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teleflex	$1.99B	2.99	-$905.64M	-$22.80	N/A
Pulse Biosciences	$350K	8,386.27	-$72.78M	-$1.10	N/A

In the previous week, Teleflex had 21 more articles in the media than Pulse Biosciences. MarketBeat recorded 27 mentions for Teleflex and 6 mentions for Pulse Biosciences. Teleflex's average media sentiment score of 0.73 beat Pulse Biosciences' score of -0.46 indicating that Teleflex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teleflex	9 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pulse Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Teleflex has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.61, suggesting that its stock price is 61% more volatile than the broader market.

Pulse Biosciences has a net margin of 0.00% compared to Teleflex's net margin of -35.88%. Teleflex's return on equity of 13.29% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teleflex	-35.88%	13.29%	6.55%
Pulse Biosciences	N/A	-86.67%	-73.61%

Teleflex currently has a consensus price target of $149.80, suggesting a potential upside of 11.37%. Pulse Biosciences has a consensus price target of $32.33, suggesting a potential downside of 23.76%. Given Teleflex's higher possible upside, equities research analysts plainly believe Teleflex is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teleflex	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Teleflex beats Pulse Biosciences on 10 of the 17 factors compared between the two stocks.

How does Pulse Biosciences compare to MiniMed Group?

Pulse Biosciences (NASDAQ:PLSE) and MiniMed Group (NASDAQ:MMED) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

Pulse Biosciences currently has a consensus target price of $32.33, suggesting a potential downside of 23.76%. MiniMed Group has a consensus target price of $21.62, suggesting a potential upside of 10.28%. Given MiniMed Group's stronger consensus rating and higher possible upside, analysts clearly believe MiniMed Group is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
MiniMed Group	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

77.0% of Pulse Biosciences shares are owned by institutional investors. 74.0% of Pulse Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Pulse Biosciences had 5 more articles in the media than MiniMed Group. MarketBeat recorded 6 mentions for Pulse Biosciences and 1 mentions for MiniMed Group. MiniMed Group's average media sentiment score of 1.34 beat Pulse Biosciences' score of -0.46 indicating that MiniMed Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulse Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MiniMed Group	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pulse Biosciences has higher earnings, but lower revenue than MiniMed Group. Pulse Biosciences is trading at a lower price-to-earnings ratio than MiniMed Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350K	8,386.27	-$72.78M	-$1.10	N/A
MiniMed Group	$3.10B	1.77	-$333M	-$0.68	N/A

MiniMed Group's return on equity of 0.00% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	N/A	-86.67%	-73.61%
MiniMed Group	N/A	N/A	N/A

Summary

MiniMed Group beats Pulse Biosciences on 9 of the 14 factors compared between the two stocks.

How does Pulse Biosciences compare to LivaNova?

Pulse Biosciences (NASDAQ:PLSE) and LivaNova (NASDAQ:LIVN) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Pulse Biosciences has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market. Comparatively, LivaNova has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market.

LivaNova has a net margin of 12.82% compared to Pulse Biosciences' net margin of 0.00%. LivaNova's return on equity of 16.36% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	N/A	-86.67%	-73.61%
LivaNova	12.82%	16.36%	7.76%

Pulse Biosciences has higher earnings, but lower revenue than LivaNova. Pulse Biosciences is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350K	8,386.27	-$72.78M	-$1.10	N/A
LivaNova	$1.39B	3.02	-$242.47M	$1.95	39.09

Pulse Biosciences currently has a consensus price target of $32.33, suggesting a potential downside of 23.76%. LivaNova has a consensus price target of $83.50, suggesting a potential upside of 9.55%. Given LivaNova's stronger consensus rating and higher possible upside, analysts plainly believe LivaNova is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
LivaNova	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73

77.0% of Pulse Biosciences shares are held by institutional investors. Comparatively, 97.6% of LivaNova shares are held by institutional investors. 74.0% of Pulse Biosciences shares are held by insiders. Comparatively, 0.4% of LivaNova shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, LivaNova had 10 more articles in the media than Pulse Biosciences. MarketBeat recorded 16 mentions for LivaNova and 6 mentions for Pulse Biosciences. LivaNova's average media sentiment score of 0.92 beat Pulse Biosciences' score of -0.46 indicating that LivaNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulse Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LivaNova	6 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

LivaNova beats Pulse Biosciences on 13 of the 17 factors compared between the two stocks.

How does Pulse Biosciences compare to Integer?

Pulse Biosciences (NASDAQ:PLSE) and Integer (NYSE:ITGR) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Integer has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350K	8,386.27	-$72.78M	-$1.10	N/A
Integer	$1.85B	2.29	$102.81M	$4.01	31.19

Pulse Biosciences presently has a consensus price target of $32.33, suggesting a potential downside of 23.76%. Integer has a consensus price target of $109.86, suggesting a potential downside of 12.16%. Given Integer's higher probable upside, analysts clearly believe Integer is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Integer	0 Sell rating(s)	13 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.07

Integer has a net margin of 6.97% compared to Pulse Biosciences' net margin of 0.00%. Integer's return on equity of 12.79% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	N/A	-86.67%	-73.61%
Integer	6.97%	12.79%	6.48%

Pulse Biosciences has a beta of 1.61, suggesting that its share price is 61% more volatile than the broader market. Comparatively, Integer has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

77.0% of Pulse Biosciences shares are held by institutional investors. Comparatively, 99.3% of Integer shares are held by institutional investors. 74.0% of Pulse Biosciences shares are held by insiders. Comparatively, 1.1% of Integer shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Integer had 29 more articles in the media than Pulse Biosciences. MarketBeat recorded 35 mentions for Integer and 6 mentions for Pulse Biosciences. Integer's average media sentiment score of 0.69 beat Pulse Biosciences' score of -0.46 indicating that Integer is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulse Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Integer	17 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Integer beats Pulse Biosciences on 11 of the 16 factors compared between the two stocks.

Get Pulse Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLSE vs. The Competition

Export

Metric	Pulse Biosciences	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.94B	$5.74B	$6.98B	$13.00B
Dividend Yield	N/A	1.78%	2.59%	9.93%
P/E Ratio	-38.55	24.38	270.86	26.05
Price / Sales	8,386.27	68.27	662.75	111.30
Price / Cash	N/A	32.43	71.89	50.37
Price / Book	35.64	5.69	13.24	6.24
Net Income	-$72.78M	$148.49M	$3.45B	$342.55M
7 Day Performance	20.72%	4.55%	4.62%	4.29%
1 Month Performance	51.30%	-0.09%	-1.59%	-1.06%
1 Year Performance	188.11%	10.01%	77.38%	22.47%

Pulse Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLSE Pulse Biosciences	1.3187 of 5 stars	$42.41 +10.9%	$32.33 -23.8%	+149.3%	$2.94B	$350K	N/A	140	News Coverage Earnings Report High Trading Volume
GKOS Glaukos	1.8191 of 5 stars	$170.20 -0.4%	$177.33 +4.2%	+93.1%	$10.08B	$507.44M	N/A	1,094
TFX Teleflex	3.2022 of 5 stars	$140.07 +0.3%	$148.90 +6.3%	+24.3%	$6.18B	$1.99B	N/A	15,500	Trending News Earnings Report Dividend Announcement Analyst Forecast
MMED MiniMed Group	2.4878 of 5 stars	$18.99 -0.6%	$21.62 +13.8%	N/A	$5.33B	$3.10B	N/A	8,000
LIVN LivaNova	3.169 of 5 stars	$85.32 +3.5%	$81.38 -4.6%	+60.0%	$4.53B	$1.39B	43.75	3,300	Positive News Earnings Report Analyst Forecast High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLSE) was last updated on 8/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pulse Biosciences (PLSE) Competitors

PLSE vs. GKOS, TFX, MMED, LIVN, and ITGR

How does Pulse Biosciences compare to Glaukos?

Summary

How does Pulse Biosciences compare to Teleflex?

Summary

How does Pulse Biosciences compare to MiniMed Group?

Summary

How does Pulse Biosciences compare to LivaNova?

Summary

How does Pulse Biosciences compare to Integer?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLSE vs. The Competition

Pulse Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pulse Biosciences (PLSE) Competitors

PLSE vs. GKOS, TFX, MMED, LIVN, and ITGR

How does Pulse Biosciences compare to Glaukos?

Is GKOS or PLSE more profitable?

Do institutionals and insiders hold more shares of GKOS or PLSE?

Do analysts prefer GKOS or PLSE?

Does the media favor GKOS or PLSE?

Which has preferable valuation & earnings, GKOS or PLSE?

Which has more risk & volatility, GKOS or PLSE?

Summary

How does Pulse Biosciences compare to Teleflex?

Do insiders & institutionals hold more shares of TFX or PLSE?

Which has higher valuation and earnings, TFX or PLSE?

Does the media refer more to TFX or PLSE?

Which has more volatility and risk, TFX or PLSE?

Is TFX or PLSE more profitable?

Do analysts rate TFX or PLSE?

Summary

How does Pulse Biosciences compare to MiniMed Group?

Do analysts prefer PLSE or MMED?

Do institutionals and insiders hold more shares of PLSE or MMED?

Does the media refer more to PLSE or MMED?

Which has higher earnings & valuation, PLSE or MMED?

Is PLSE or MMED more profitable?

Summary

How does Pulse Biosciences compare to LivaNova?

Which has more volatility & risk, PLSE or LIVN?

Is PLSE or LIVN more profitable?

Which has stronger valuation and earnings, PLSE or LIVN?

Do analysts rate PLSE or LIVN?

Do insiders and institutionals hold more shares of PLSE or LIVN?

Does the media prefer PLSE or LIVN?

Summary

How does Pulse Biosciences compare to Integer?

Which has better earnings and valuation, PLSE or ITGR?

Do analysts prefer PLSE or ITGR?

Is PLSE or ITGR more profitable?

Which has more risk and volatility, PLSE or ITGR?

Do insiders and institutionals hold more shares of PLSE or ITGR?

Does the media prefer PLSE or ITGR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLSE vs. The Competition

Pulse Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools